Prostate Cancer P D:经会阴和经直肠MRI-US融合活检在前列腺癌检测中的准确性研究

2020-01-28 AlexYang MedSci原创

核磁共振成像(MRI)和超声(US)融合前列腺活检可以通过经会阴(TR-融合)或者经直肠(TP-融合)的方法来进行。目前来讲,前瞻性的比较性证据仍旧有限。最近,有研究人员比较了指数病变内TR和TP融合在临床显著性前列腺癌(csPCa)中的检出率情况。研究是一个前瞻性的、非虐性和人之间的试验,共有77名患者完成了整个过程。平均年龄为68.2岁(IQR:64.2-72.2),平均PSA为8.9ng/m

核磁共振成像(MRI)和超声(US)融合前列腺活检可以通过经会阴(TR-融合)或者经直肠(TP-融合)的方法来进行。目前来讲,前瞻性的比较性证据仍旧有限。最近,有研究人员比较了指数病变内TR和TP融合在临床显著性前列腺癌(csPCa)中的检出率情况。

研究是一个前瞻性的、非虐性和人之间的试验,共有77名患者完成了整个过程。平均年龄为68.2岁(IQR:64.2-72.2),平均PSA为8.9ng/ml(IQR:6.18-12.2)。10名患者(13%)没有进行过活检,其他的患者(87%)之前均经历过活检。研究人员在32名患者(42%)中检出了csPCa,且所有的案例均可以通过TP融合的方法检出,而TR融合方法只能检出其中20名患者(26%)。CsPCa诊断的绝对差为15.6(CI 90% 27.9-3.2%),且TP融合表现更好(P=0.029)。因此,TP融合检测效果不亚于TR融合检测。另外TP融合和TR融合90%置信区间的下界大于0,因此TP融合更优。探索性亚群分析表明了TP融合在患者和指数病变衍生亚群(大小、位置、PI-RADS、PAS和活检历史)中比TR融合的检出csPCa比例更高。

最后,研究人员指出,TP融合活检效果好,且在检测MRI可见指数病变的csPCa中比TR融合方法效果更好。因此,有TP和TR融合经验的中心在选择活检方法时应考虑这些结果。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791601, encodeId=6de61e9160139, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 19 20:09:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905971, encodeId=429819059e143, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Apr 28 07:09:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278180, encodeId=e87b12e8180e3, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364558, encodeId=12c0136455843, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513685, encodeId=36c715136853a, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525527, encodeId=745c152552e35, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602231, encodeId=1cc0160223114, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040654, encodeId=fc2210406547d, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jan 28 16:09:00 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791601, encodeId=6de61e9160139, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 19 20:09:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905971, encodeId=429819059e143, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Apr 28 07:09:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278180, encodeId=e87b12e8180e3, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364558, encodeId=12c0136455843, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513685, encodeId=36c715136853a, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525527, encodeId=745c152552e35, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602231, encodeId=1cc0160223114, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040654, encodeId=fc2210406547d, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jan 28 16:09:00 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791601, encodeId=6de61e9160139, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 19 20:09:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905971, encodeId=429819059e143, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Apr 28 07:09:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278180, encodeId=e87b12e8180e3, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364558, encodeId=12c0136455843, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513685, encodeId=36c715136853a, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525527, encodeId=745c152552e35, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602231, encodeId=1cc0160223114, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040654, encodeId=fc2210406547d, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jan 28 16:09:00 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791601, encodeId=6de61e9160139, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 19 20:09:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905971, encodeId=429819059e143, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Apr 28 07:09:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278180, encodeId=e87b12e8180e3, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364558, encodeId=12c0136455843, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513685, encodeId=36c715136853a, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525527, encodeId=745c152552e35, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602231, encodeId=1cc0160223114, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040654, encodeId=fc2210406547d, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jan 28 16:09:00 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
    2020-01-30 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1791601, encodeId=6de61e9160139, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 19 20:09:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905971, encodeId=429819059e143, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Apr 28 07:09:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278180, encodeId=e87b12e8180e3, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364558, encodeId=12c0136455843, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513685, encodeId=36c715136853a, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525527, encodeId=745c152552e35, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602231, encodeId=1cc0160223114, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040654, encodeId=fc2210406547d, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jan 28 16:09:00 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1791601, encodeId=6de61e9160139, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 19 20:09:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905971, encodeId=429819059e143, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Apr 28 07:09:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278180, encodeId=e87b12e8180e3, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364558, encodeId=12c0136455843, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513685, encodeId=36c715136853a, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525527, encodeId=745c152552e35, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602231, encodeId=1cc0160223114, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040654, encodeId=fc2210406547d, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jan 28 16:09:00 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
    2020-01-30 licz0427
  7. [GetPortalCommentsPageByObjectIdResponse(id=1791601, encodeId=6de61e9160139, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 19 20:09:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905971, encodeId=429819059e143, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Apr 28 07:09:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278180, encodeId=e87b12e8180e3, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364558, encodeId=12c0136455843, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513685, encodeId=36c715136853a, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525527, encodeId=745c152552e35, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602231, encodeId=1cc0160223114, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040654, encodeId=fc2210406547d, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jan 28 16:09:00 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
    2020-01-30 sunylz
  8. [GetPortalCommentsPageByObjectIdResponse(id=1791601, encodeId=6de61e9160139, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Sep 19 20:09:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905971, encodeId=429819059e143, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Apr 28 07:09:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278180, encodeId=e87b12e8180e3, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364558, encodeId=12c0136455843, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513685, encodeId=36c715136853a, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525527, encodeId=745c152552e35, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602231, encodeId=1cc0160223114, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 30 04:09:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040654, encodeId=fc2210406547d, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jan 28 16:09:00 CST 2020, time=2020-01-28, status=1, ipAttribution=)]
    2020-01-28 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Sci Rep:循环miR-141和miR-375与转移去势抵抗性前列腺癌的治疗结果相关

转移去势抵抗性前列腺癌(mCPRC)与高的死亡率相关,而疾病活性的控制到目前为止仍旧是一个主要的临床挑战。小RNA(miRs)在前列腺癌的诊断和预后中的作用已经有广泛的研究。最近,有研究人员在mCRPC患者中调查了循环miRs与治疗结果的关系。研究人员调查了84名mCRPC患者血浆样本中5个miRs(miR-93-5p、- 125b1 -5p、-141-3p、-221-3p和miR-375-3p)

盘点:前列腺癌治疗方法进展

【1】Sci Rep:盆腔淋巴结清扫术对前列腺患者益处分析 盆腔淋巴结清扫术(PLND)是前列腺癌淋巴结分期的金标准,并且需要在淋巴结浸润(LNI)可能性>5%的患者中进行。然而,PLND的治疗作用和作用程度仍旧存在争议。最近,有研究人员回顾性的分析了2010年到2015年经历和没有经历PLND的20688名进行了根治性前列腺切除(RP)的患者。所有的患者LNI>

Communications Biology:NQO1衰减能够加重前列腺癌和肿瘤细胞的可塑性

NAD (P) H:醌氧化还原酶1(NQO1)能够响应应激来调控细胞命运决定。氧化应激能够支持癌症维持和进展。之前的研究表明了前列腺癌细胞中NQO1(NQO1low)的敲除能够上调促炎细胞因子和激素阻断条件下细胞的生存。最近,有研究人员测试了NQO1low细胞形成肿瘤的能力。研究发现,与NQO1high细胞相比,NQO1low细胞能够形成恶性肿瘤。生物学活检和循环肿瘤细胞表明了前列腺癌的生化复发与

Prostate Cancer P D:高风险前列腺癌中GLUT1的表达分析

肿瘤18F-FDG摄取在高风险和转移前列腺癌(PCa)中具有预后价值。最近,有研究人员调查了PCa中18F-FDG摄取对PET/CT成像潜在的葡萄糖代谢机制。研究是一个回顾性的分析,包括了94名诊断为格林森总和≥8的前列腺癌患者,他们均在根治性前列腺切除术前经历了18F-FDG-PET/CT成像。研究的平均跟踪调查时间为4.5年,56%的患者(n=53)具有生化复发(BCR),7%(n=7)的患者

Oncogene:BCOR偶联H2A单泛素化来抑制雄激素受体靶标基因来调控前列腺癌增殖

有研究人员已经鉴定了BCL6共阻遏物(BCOR)是一个激素依赖的雄激素受体(AR)互作伴侣,并且是正常前列腺和癌变前列腺发展的关键转录因子。BCOR在癌症和血液疾病中经常突变,并且是非典型多梳抑制复合物1(ncPRC1.1)的组分,对细胞分化的多个方面是需要的。然而,其在雄激素信号或者前列腺癌细胞中的作用仍旧未知。最近,有研究人员利用全基因组分析的方法阐释了在去势难治性前列腺癌(CRPC)中,BC

Sci Rep:先进的放疗技术和剂量增强对根治性前列腺切除术后挽救治疗毒性的影响

剂量递增放疗与强度调节放疗(IMRT)和成像指导的放疗(IGRT)的安全性和疗效在根治性前列腺切除术后挽救治疗(SRT)中仍旧不清楚。最近,有研究人员调查了这些先进的放疗技术和剂量增强对SRT毒性的影响。他们的多机构回顾性研究包括了421名患者,他们经历了SRT手术,平均剂量为66Gy。IMRT和IGRT分别用于225名患者(53%)和321名患者(T76%)。在平均跟踪调查的50个月中,晚期2级